| Autor: |
Chiurazzi M; Department of Clinical Medicine and Surgery, Physiology Nutrition Unit, Federico II University of Naples, 80131 Naples, Italy., Cacciapuoti N; Department of Clinical Medicine and Surgery, Physiology Nutrition Unit, Federico II University of Naples, 80131 Naples, Italy., Di Lauro M; Department of Clinical Medicine and Surgery, Physiology Nutrition Unit, Federico II University of Naples, 80131 Naples, Italy., Nasti G; Department of Clinical Medicine and Surgery, Physiology Nutrition Unit, Federico II University of Naples, 80131 Naples, Italy., Ceparano M; Department of Clinical Medicine and Surgery, Physiology Nutrition Unit, Federico II University of Naples, 80131 Naples, Italy., Salomone E; Department of Clinical Medicine and Surgery, Physiology Nutrition Unit, Federico II University of Naples, 80131 Naples, Italy., Guida B; Department of Clinical Medicine and Surgery, Physiology Nutrition Unit, Federico II University of Naples, 80131 Naples, Italy., Lonardo MS; Department of Clinical Medicine and Surgery, Physiology Nutrition Unit, Federico II University of Naples, 80131 Naples, Italy. |
| Abstrakt: |
Overweight/obesity is often associated with a non-alcoholic fatty liver disease (NAFLD). The study aim was to investigate the effects of a nutraceutical supplementation associated to a Mediterranean-hypocaloric-diet (MHD) on ultrasound-liver-steatosis (ULS) grade improvement in overweight/obese patients with NAFLD. A total of 68 subjects (BMI ≥ 25 kg/m2) with NAFLD were recruited, randomized into 2 groups and treated for 3 months: the Nutraceutical group was treated with MHD plus nutraceutical supplementation (Vitamin E, L-glutathione, silymarin and hepato-active compounds); the Control-group only with a MHD. Anthropometric measurements, body composition, biochemical parameters and Hepatic steatosis index (HSI) were evaluated at baseline and after 3 months; patients with HSI >36 underwent a liver ultrasound to determine liver steatosis grade (3 severe, 2 moderate, 1 mild). In all patients, a significant improvement in nutritional and biochemical parameters was observed after treatment. After treatment, the nutraceutical group showed a significant improvement in hepatic steatosis, either according to ULS-grade (11.1% and 5.6% of patients with mild and moderate liver steatosis, respectively, showed a complete NAFLD regression; 33.3% and 22.2% of patients with moderate and severe liver steatosis, respectively showed a regression to mild liver steatosis), or according to HSI (49.3 ± 10.1 vs. 43.3 ± 9.0, p = 0.01), suggesting that a healthy diet is still the best choice, although the use of specific supplements can enhance the efficacy of dietary intervention in overweight/obese patients with NAFLD. |
